MarketAZD-2327
Company Profile

AZD-2327

AZD-2327 is a δ-opioid receptor agonist which was under development for the treatment of depressive disorders and anxiety disorders but was never marketed. It is taken by mouth.

Pharmacology
The drug showed antidepressant-like and anxiolytic-like effects as well as locomotor-stimulating effects in animal models. In addition to its δ-opioid receptor agonist activity, AZD-2327 has been reported to act as a cytochrome P450 CYP3A4 inhibitor. It has been found to inhibit the release of norepinephrine caused by anxiety and was able to do so as much as the benzodiazepine diazepam. However, AZD-2327 could be advantageous to benzodiazepines because these drugs often cause rapid tolerance and dependence. In contrast to benzodiazepines, AZD-2327 may have less or no potential for tolerance in terms of its anxiolytic-like effects. == History ==
History
AZD-2327 was first described by 2004 and was first described in the scientific literature in 2009. AZD-2327 was developed by AstraZeneca. == See also ==
tickerdossier.comtickerdossier.substack.com